148 related articles for article (PubMed ID: 9894246)
21. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry.
Schneider J; Rubio MP; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
Eur J Cancer; 1994; 30A(4):504-8. PubMed ID: 8018409
[TBL] [Abstract][Full Text] [Related]
22. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
23. Correlation of p53 mutations in ThinPrep-processed fine needle breast aspirates with surgically resected breast cancers.
Pollett A; Bedard YC; Li SQ; Rohan T; Kandel R
Mod Pathol; 2000 Nov; 13(11):1173-9. PubMed ID: 11106073
[TBL] [Abstract][Full Text] [Related]
24. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast.
Done SJ; Eskandarian S; Bull S; Redston M; Andrulis IL
J Natl Cancer Inst; 2001 May; 93(9):700-4. PubMed ID: 11333292
[TBL] [Abstract][Full Text] [Related]
25. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
26. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
[TBL] [Abstract][Full Text] [Related]
27. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing.
Chakravarty G; Redkar A; Mittra I
Br J Cancer; 1996 Oct; 74(8):1181-7. PubMed ID: 8883402
[TBL] [Abstract][Full Text] [Related]
30. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
31. Mutations of the p53 gene in male breast cancer.
Anelli A; Anelli TF; Youngson B; Rosen PP; Borgen PI
Cancer; 1995 May; 75(9):2233-8. PubMed ID: 7712430
[TBL] [Abstract][Full Text] [Related]
32. p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer.
Nayak BK; Baral RN; Das BR
Neoplasma; 1996; 43(5):305-10. PubMed ID: 8996549
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
34. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
35. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
36. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis.
Bosari S; Marchetti A; Buttitta F; Graziani D; Borsani G; Loda M; Bevilacqua G; Coggi G
Diagn Mol Pathol; 1995 Dec; 4(4):249-55. PubMed ID: 8634780
[TBL] [Abstract][Full Text] [Related]
37. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
39. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
